SAN FRANCISCO, March 19, 2018 /PRNewswire/ -- Kamedis™, a provider of advanced botanical solutions for chronic skin disorders,
The Kamedis product lines currently being introduced in the U.S. have been clinically proven to reduce eczema flare-ups up to 50% in two weeks, acne lesions within 12 hours, and dandruff by 50% in two weeks without complications like drying, flaking and irritation or undesirable ingredients such as benzoyl peroxide, sodium lauryl sulfate, parabens, steroids, dyes and coal tar.
The new U.S. medical advisory board uniquely combines dermatologists and naturopaths, reflecting Kamedis' melding of different approaches to medical challenges. Board members will supply scientific and medical expertise as well as strategic advice to assist Kamedis in building its U.S. market presence. Members include:
"We introduced our first products in Israel in 2007 and since then have expanded to China, Taiwan, Hong Kong, Switzerland and the Philippines. The U.S. market presents a whole new set of challenges and opportunities," said Kamedis Inc. CEO Roni Kramer, a traditional Chinese medicine practitioner who founded the company after discovering that botanicals helped dermatologic patients who experienced side effects or no relief from conventional products. "Our medical advisory board will be instrumental in guiding our efforts to establish the brand here, support ongoing product development and clinical trial initiatives, and ensure that consumers have truly effective nonsteroidal alternatives to treat chronic skin disorders."
Kamedis develops effective, dermatologist-tested, botanical skincare products for a variety of chronic skin conditions including eczema, acne, dandruff, psoriasis, dry skin and itchy/irritated skin. Launched in Israel in 2003 and now sold worldwide, the company's products are based on extensive scientific research and development that included testing hundreds of traditional Chinese medicine botanicals and their combinations. The botanicals are produced in an ISO 13485- and ISO 9001-certified manufacturing facility ensuring quality and production consistency of botanical extracts. The unique extraction technique is developed to maximize formulation potency. All final products have been validated by dermatologists, are backed by dozens of clinical trials, and have received strong endorsement from consumers. For more information, visit https://kamedis-usa.com or email firstname.lastname@example.org.
View original content:http://www.prnewswire.com/news-releases/botanical-dermatology-brand-kamedis-forms-us-medical-advisory-board-300615931.html
Subscribe to our Free Newsletters!
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...View All